<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00931242</url>
  </required_header>
  <id_info>
    <org_study_id>AD / CD</org_study_id>
    <secondary_id>AP-ECZ-PI-0030</secondary_id>
    <nct_id>NCT00931242</nct_id>
  </id_info>
  <brief_title>Study of Apremilast in Atopic or Contact Dermatitis</brief_title>
  <official_title>A Phase 2, Open-label, Investigator-Initiated Study to Evaluate the Safety and Efficacy of Apremilast in Subjects With Recalcitrant Contact or Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tufts Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Tufts Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the efficacy of apremilast in patients with&#xD;
      recalcitrant atopic or contact dermatitis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Atopic Dermatitis (AD) is a chronic, inflammatory skin disease characterized by dry, red, and&#xD;
      itchy patches that can become thickened and lichenified with time. Contact Dermatitis, or&#xD;
      Allergic Contact Dermatitis (ACD), is an eczematous reaction in response to an environmental&#xD;
      allergen.&#xD;
&#xD;
      The etiology of Atopic Dermatitis (AD) and Allergic Contact Dermatitis (ACD) has not been&#xD;
      completely elucidated, and new understandings of underlying mechanisms have expanded and&#xD;
      focused treatment regimens and paradigms.&#xD;
&#xD;
      Atopic Dermatitis (AD) is thought to be mediated by Th2 type T cells elaborating a number of&#xD;
      cytokines which are blocked in vitro by apremilast. The chronic Atopic Dermatitis (AD)&#xD;
      pathway may involve a change to Th1 cytokines. Genetic factors do not contribute as much to&#xD;
      the course of Allergic Contact Dermatitis (ACD) as in Atopic Dermatitis (AD). Rather,&#xD;
      Allergic Contact Dermatitis (ACD) is a type IV, T-cell mediated, delayed-hypersensitivity&#xD;
      reaction that can be self-limited. Similar to Atopic Dermatitis (AD), a number of&#xD;
      pro-inflammatory cytokines are involved in recruiting T cells preferentially to the skin: Th1&#xD;
      cytokines, Th2 cytokines, CD8 cytokines, and T-regulatory cytokines. These pathways in&#xD;
      Allergic Contact Dermatitis (ACD) are activated by IFN-γ, driven by TNF-α, and as above,&#xD;
      apremilast has been shown to block these cytokines in vitro.&#xD;
&#xD;
      Current treatments for Atopic Dermatitis (AD) and Allergic Contact Dermatitis (ACD) include&#xD;
      skin care, trigger avoidance (especially in the case of ACD), topical corticosteroids,&#xD;
      steroid sparing treatments, antihistamines, topical and systemic antibiotics, and ultraviolet&#xD;
      light. For more recalcitrant Atopic Dermatitis (AD) and Allergic Contact Dermatitis&#xD;
      (ACD)cases, several immunosuppressive treatments exist.&#xD;
&#xD;
      Subjects with recalcitrant Atopic Dermatitis (AD) or Allergic Contact Dermatitis (ACD)have&#xD;
      exhausted conventional systemic treatment options because they do not respond to conventional&#xD;
      systemic therapy or cannot use these agents due to side effects or cumulative toxicity.&#xD;
&#xD;
      There is an urgent need to evaluate new therapeutic options in recalcitrant Atopic Dermatitis&#xD;
      (AD) and Allergic Contact Dermatitis (ACD). Very few of the available drugs for recalcitrant&#xD;
      Atopic Dermatitis (AD) and Allergic Contact Dermatitis (ACD) have reasonable efficacy and&#xD;
      safety profiles in this condition, are easily available, or easy to administer. A new&#xD;
      treatment strategy is needed for the treatment of recalcitrant contact or atopic dermatitis&#xD;
      that would increase efficacy, minimize toxicity for both short and long-term treatment, and&#xD;
      be easy to administer. The availability of alternative drug treatment(s) offering safe and&#xD;
      effective short and long-term management would significantly benefit subjects with&#xD;
      recalcitrant contact or atopic dermatitis.&#xD;
&#xD;
      This study uses a novel oral agent (apremilast) that modulates multiple anti-inflammatory&#xD;
      pathways through targeted phosphodiesterase type IV (PDE4) inhibition decreased expression of&#xD;
      dermatitis. Apremilast has pharmacodynamic properties with a potential therapeutic benefit&#xD;
      for treating inflammatory autoimmune disorders that involve elevated serum cytokine levels,&#xD;
      including Atopic Dermatitis (AD) and Allergic Contact Dermatitis (ACD).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients Achieving an Improvement (Decrease) in IGA (Investigator Global Assessment) by Two or More Points</measure>
    <time_frame>12 weeks</time_frame>
    <description>Improvement in IGA (Investigator Global Assessment) by two or more points on a five point scale, with 0 being no disease activity and 5 being maximum disease activity, at week 12</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Achieving 75% Reduction in Eczema Area and Severity Index (EASI) Score at Week 12 in Reference to Week 0</measure>
    <time_frame>12 weeks</time_frame>
    <description>EASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, edema, lichenification, and excoriations/erosions are scored on a scale of 0 (none) to 3 (severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 to 6. The total qualitative score is multiplied by the degree of involvement for each anatomic region and then multiplied by a constant and summed to yield the EASI score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Achieving 50% Reduction in Eczema Area and Severity Index (EASI) Score at Week 12 in Reference to Week 0</measure>
    <time_frame>12 weeks</time_frame>
    <description>EASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, edema, lichenification, and excoriations/erosions are scored on a scale of 0 (none) to 3 (severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 to 6. The total qualitative score is multiplied by the degree of involvement for each anatomic region and then multiplied by a constant and summed to yield the EASI score.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Atopic Dermatitis</condition>
  <condition>Allergic Contact Dermatitis</condition>
  <arm_group>
    <arm_group_label>Apremilast</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apremilast is being evaluated at daily doses of 20 mg by mouth (PO) twice daily (BID) for 12 weeks of treatment (treatment phase) in subjects with recalcitrant plaque-type Atopic Dermatitis (AD) or Allergic Contact Ddermatitis (ACD).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apremilast</intervention_name>
    <description>Apremilast is being evaluated at daily doses of 20 mg by mouth (PO) twice daily (BID) for 12 weeks of treatment (treatment phase) in subjects with recalcitrant plaque-type Atopic Dermatitis (AD) or Allergic Contact Ddermatitis (ACD).</description>
    <arm_group_label>Apremilast</arm_group_label>
    <other_name>CC-10004 (apremilast)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must understand and voluntarily sign an informed consent form.&#xD;
&#xD;
          -  Must be male or female and aged ≥ 18 years at time of consent.&#xD;
&#xD;
          -  Must be able to adhere to the study visit schedule and other protocol requirements.&#xD;
&#xD;
          -  Must have a documented history of contact or atopic dermatitis for at least 3 months&#xD;
             prior to screening visit. Subjects will be asked to bring records at the time of&#xD;
             screening visit; if they do not bring these records, subjects will be asked to&#xD;
             complete and sign a release of records for which will be sent to the subject's&#xD;
             physician. The Investigators will review records to confirm eligibility prior to&#xD;
             enrolling a subject into the study.&#xD;
&#xD;
          -  Subjects must fulfill criteria outlined in at least one of the following clinical&#xD;
             categories:&#xD;
&#xD;
               -  Unresponsive to standard systemic or topical therapy, as defined by clinical&#xD;
                  history, in the investigator's opinion, i.e. inadequate response to one or more&#xD;
                  adequate treatment course (s) of standard systemic therapy including but not&#xD;
                  limited to: topical steroids, ultraviolet light A [UVA], narrowband ultraviolet B&#xD;
                  (NBUVB), ultraviolet light B [UVB].&#xD;
&#xD;
               -  Intolerant to or cannot receive (e.g., contraindication to prescribe) standard&#xD;
                  systemic or topical therapy for contact or atopic dermatitis.&#xD;
&#xD;
          -  Must have a IGA score of at least moderate (3 on a 0 to 5 point scale) at screening.&#xD;
&#xD;
          -  Must meet the following laboratory criteria:&#xD;
&#xD;
               -  White blood cell count ≥ 3000/ μL (3 x 109/L) and &lt; 14,000/ μL (&lt; 14 x 109/L)&#xD;
&#xD;
               -  Platelet count &gt; 100,000/ μL (100 x 109/L)&#xD;
&#xD;
               -  Serum creatinine ≤ 1.5 mg/dL (≤ 132.6 μmol/L)&#xD;
&#xD;
               -  AST (SGOT) and ALT (SGPT) ≤ 1.5 x upper limit of normal (ULN)&#xD;
&#xD;
               -  Hemoglobin &gt; 9 g/dL&#xD;
&#xD;
               -  Total bilirubin ≤ 2.0 mg/dL&#xD;
&#xD;
          -  Females of childbearing potential (FCBP) must have a negative urine pregnancy test at&#xD;
             screening. In addition, sexually active FCBP must agree to use TWO of the following&#xD;
             adequate forms of contraception while on study medication:&#xD;
&#xD;
               -  oral, injectable, or implantable hormonal contraceptives;&#xD;
&#xD;
               -  tubal ligation;&#xD;
&#xD;
               -  intrauterine device;&#xD;
&#xD;
               -  barrier contraceptive with spermicide;&#xD;
&#xD;
               -  vasectomized partner while on study.&#xD;
&#xD;
          -  A FCBP must agree to have pregnancy tests every 4 weeks while on study medication.&#xD;
&#xD;
          -  Males (including those who have had a vasectomy) must agree to use barrier&#xD;
             contraception (latex condoms) when engaging in sexual activity with FCBP while on&#xD;
             study medication and for 84 days after taking the last dose of study medication.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to provide voluntary consent.&#xD;
&#xD;
          -  History of clinically significant (as determined by the investigator) cardiac,&#xD;
             endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic,&#xD;
             immunologic, or other major disease. Potential subjects with severe uncontrolled&#xD;
             conditions, such as severe uncontrolled diabetes, will be excluded.&#xD;
&#xD;
          -  Any condition, including the presence of laboratory abnormalities, which places the&#xD;
             subject at unacceptable risk if he/she were to participate in the study or confounds&#xD;
             the ability to interpret data from the study.&#xD;
&#xD;
          -  Pregnant or breastfeeding.&#xD;
&#xD;
          -  Systemic fungal infection.&#xD;
&#xD;
          -  History of active mycobacterial infection with any species (including Mycobacterium&#xD;
             tuberculosis) within 3 years prior to screening visit. Subjects with Mycobacterium&#xD;
             tuberculosis infection more than 3 years prior to screening visit are allowed if&#xD;
             successful treatment was completed at least 3 years prior to randomization and is&#xD;
             documented and available for verification.&#xD;
&#xD;
          -  Latent Mycobacterium tuberculosis infection as indicated by a positive Purified&#xD;
             Protein Derivative [PPD] skin test. Subjects with a positive PPD skin test and&#xD;
             documented completion of treatment for latent TB are eligible. Subjects with a&#xD;
             positive PPD skin test and not treated or no documentation of completion of treatment&#xD;
             are ineligible.&#xD;
&#xD;
          -  If QuantiFERON® test is performed instead of the PPD test, only those with a negative&#xD;
             QuantiFERON® test are allowed in the study.&#xD;
&#xD;
          -  History of incompletely treated Mycobacterium tuberculosis infection as indicated by:&#xD;
&#xD;
               -  Subject's medical records documenting incomplete treatment for Mycobacterium&#xD;
                  tuberculosis.&#xD;
&#xD;
               -  Subject's self-reported history of incomplete treatment for Mycobacterium&#xD;
                  tuberculosis.&#xD;
&#xD;
          -  History of recurrent bacterial infection (at least 3 major infections resulting in&#xD;
             hospitalization and/or requiring intravenous antibiotic treatment within the past 2&#xD;
             years).&#xD;
&#xD;
          -  Clinically significant abnormality on the chest x-ray (CXR) at screening. Chest x-rays&#xD;
             performed within 3 months prior to start of study drug are acceptable.&#xD;
&#xD;
          -  Contact or atopic Dermatitis flare within 30 days of screening, defined as a sudden&#xD;
             intensification of contact or atopic dermatitis&#xD;
&#xD;
          -  Use of systemic therapy for contact or atopic dermatitis (including but not limited to&#xD;
             cyclosporine, corticosteroids, methotrexate, oral retinoids, mycophenolate mofetil,&#xD;
             thioguanine, hydroxyurea, sirolimus, tacrolimus, azathioprine) within 14 days of Week&#xD;
             0 (Baseline).&#xD;
&#xD;
          -  Topical therapy (including but not limited to topical steroids, topical vitamin A or D&#xD;
             analog preparations, tacrolimus, pimecrolimus, or anthralin) within 7 days of Week 0&#xD;
             (Baseline). (Exception: Class VI or VII potency corticosteroids will be allowed&#xD;
             [Appendix 18.8] for treatment of the palms, face, scalp, axillae, plantar surfaces and&#xD;
             groin in accordance with the manufacturers suggested usage, except within 24 hours of&#xD;
             a study visit. Non-medicated emollients [e.g., Eucerin®], and tar shampoo are also&#xD;
             allowed.)&#xD;
&#xD;
          -  Adalimumab, etanercept, efalizumab or infliximab use within 56 days of Week 0&#xD;
             (Baseline).&#xD;
&#xD;
          -  Alefacept use within 180 days of Week 0 (Baseline).&#xD;
&#xD;
          -  Phototherapy (PUVA, UVA,NB-UVB, UVB) within 14 days of Week 0 (Baseline).&#xD;
&#xD;
          -  Use of any investigational medication within 4 weeks prior to start of study drug or 5&#xD;
             pharmacokinetic/pharmacodynamic half-lives (whichever is longer).&#xD;
&#xD;
          -  Any clinically significant abnormality on 12-lead ECG at screening.&#xD;
&#xD;
          -  History of congenital or acquired immunodeficiency (e.g., Common Variable&#xD;
             Immunodeficiency [CVID]).&#xD;
&#xD;
          -  Hepatitis B surface antigen positive or Hepatitis B core antibody positive at&#xD;
             screening.&#xD;
&#xD;
          -  History of Human Immunodeficiency Virus (HIV) infection.&#xD;
&#xD;
          -  Antibodies to Hepatitis C at screening.&#xD;
&#xD;
          -  Malignancy or history of malignancy (except for treated [i.e., cured] basal-cell skin&#xD;
             carcinoma(s) or treated squamous-cell skin carcinomas).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alice B. Gottlieb, M.D., PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tufts Medical Center, Department of Dermatology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tufts Medical Center, Department of Dermatology</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.tuftsmedicalcenter.org/OurServices/Dermatology/default?Page=5</url>
    <description>Tufts Medical Center, Department of Dermatology, Research</description>
  </link>
  <reference>
    <citation>Leung DY, Boguniewicz M, Howell MD, Nomura I, Hamid QA. New insights into atopic dermatitis. J Clin Invest. 2004 Mar;113(5):651-7. Review.</citation>
    <PMID>14991059</PMID>
  </reference>
  <reference>
    <citation>Novak N, Bieber T, Leung DY. Immune mechanisms leading to atopic dermatitis. J Allergy Clin Immunol. 2003 Dec;112(6 Suppl):S128-39. Review.</citation>
    <PMID>14657843</PMID>
  </reference>
  <reference>
    <citation>Girolomoni G, Sebastiani S, Albanesi C, Cavani A. T-cell subpopulations in the development of atopic and contact allergy. Curr Opin Immunol. 2001 Dec;13(6):733-7. Review.</citation>
    <PMID>11677098</PMID>
  </reference>
  <reference>
    <citation>Cavani A, Albanesi C, Traidl C, Sebastiani S, Girolomoni G. Effector and regulatory T cells in allergic contact dermatitis. Trends Immunol. 2001 Mar;22(3):118-20.</citation>
    <PMID>11286716</PMID>
  </reference>
  <reference>
    <citation>Cone RE, Li X, Sharafieh R, O'Rourke J, Vella AT. The suppression of delayed-type hypersensitivity by CD8+ regulatory T cells requires interferon-gamma. Immunology. 2007 Jan;120(1):112-9. Epub 2006 Oct 18.</citation>
    <PMID>17052246</PMID>
  </reference>
  <reference>
    <citation>Jung T, Stingl G. Atopic dermatitis: therapeutic concepts evolving from new pathophysiologic insights. J Allergy Clin Immunol. 2008 Dec;122(6):1074-81. doi: 10.1016/j.jaci.2008.09.042. Epub 2008 Nov 6. Review.</citation>
    <PMID>18992925</PMID>
  </reference>
  <reference>
    <citation>Belloni B, Andres C, Ollert M, Ring J, Mempel M. Novel immunological approaches in the treatment of atopic eczema. Curr Opin Allergy Clin Immunol. 2008 Oct;8(5):423-7. doi: 10.1097/ACI.0b013e32830fb8fd. Review.</citation>
    <PMID>18769195</PMID>
  </reference>
  <reference>
    <citation>Harada D, Takada C, Nosaka Y, Takashima Y, Kobayashi K, Takaba K, Manabe H. Effect of orally administered KF66490, a phosphodiesterase 4 inhibitor, on dermatitis in mouse models. Int Immunopharmacol. 2009 Jan;9(1):55-62. doi: 10.1016/j.intimp.2008.09.011. Epub 2008 Oct 12.</citation>
    <PMID>18854230</PMID>
  </reference>
  <reference>
    <citation>Schmitt J, Langan S, Williams HC; European Dermato-Epidemiology Network. What are the best outcome measurements for atopic eczema? A systematic review. J Allergy Clin Immunol. 2007 Dec;120(6):1389-98. Epub 2007 Oct 1. Review.</citation>
    <PMID>17910890</PMID>
  </reference>
  <reference>
    <citation>Gottlieb AB, Strober B, Krueger JG, Rohane P, Zeldis JB, Hu CC, Kipnis C. An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast. Curr Med Res Opin. 2008 May;24(5):1529-38. doi: 10.1185/030079908X301866 . Epub 2008 Apr 16.</citation>
    <PMID>18419879</PMID>
  </reference>
  <verification_date>November 2010</verification_date>
  <study_first_submitted>June 30, 2009</study_first_submitted>
  <study_first_submitted_qc>July 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2009</study_first_posted>
  <results_first_submitted>October 28, 2010</results_first_submitted>
  <results_first_submitted_qc>November 23, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 20, 2010</results_first_posted>
  <last_update_submitted>November 23, 2010</last_update_submitted>
  <last_update_submitted_qc>November 23, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 20, 2010</last_update_posted>
  <responsible_party>
    <name_title>Alice B. Gottlieb, MD, PhD</name_title>
    <organization>Tufts Medical Center</organization>
  </responsible_party>
  <keyword>eczema</keyword>
  <keyword>dermatitis</keyword>
  <keyword>TNF blockade</keyword>
  <keyword>PDE4 inhibitor</keyword>
  <keyword>T cell inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
    <mesh_term>Dermatitis, Contact</mesh_term>
    <mesh_term>Dermatitis, Allergic Contact</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Apremilast</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Apremilast</title>
          <description>Apremilast is being evaluated at daily doses of 20 mg PO twice daily (BID) for 12 weeks of treatment (treatment phase) in subjects with recalcitrant plaque-type AD or ACD.</description>
        </group>
        <group group_id="P2">
          <title>Screen Failures</title>
          <description>Patients who were screened but failed to meet inclusion criteria for the study</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Apremilast</title>
          <description>Apremilast is being evaluated at daily doses of 20 mg PO (by mouth) twice daily (BID) for 12 weeks of treatment (treatment phase) in subjects with recalcitrant plaque-type atopic dermatitis or allergic contact dermatitis.</description>
        </group>
        <group group_id="B2">
          <title>Screen Failures</title>
          <description>Subjects that were screened but failed to meet inclusion criteria for the study.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.3" spread="14.2442971"/>
                    <measurement group_id="B2" value="53.4" spread="4.5"/>
                    <measurement group_id="B3" value="45" spread="13.0384048"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Achieving an Improvement (Decrease) in IGA (Investigator Global Assessment) by Two or More Points</title>
        <description>Improvement in IGA (Investigator Global Assessment) by two or more points on a five point scale, with 0 being no disease activity and 5 being maximum disease activity, at week 12</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Apremilast</title>
            <description>Apremilast is being evaluated at daily doses of 20 mg PO twice daily (BID) for 12 weeks of treatment (treatment phase) in subjects with recalcitrant plaque-type AD or ACD.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Achieving an Improvement (Decrease) in IGA (Investigator Global Assessment) by Two or More Points</title>
          <description>Improvement in IGA (Investigator Global Assessment) by two or more points on a five point scale, with 0 being no disease activity and 5 being maximum disease activity, at week 12</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Achieving 75% Reduction in Eczema Area and Severity Index (EASI) Score at Week 12 in Reference to Week 0</title>
        <description>EASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, edema, lichenification, and excoriations/erosions are scored on a scale of 0 (none) to 3 (severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 to 6. The total qualitative score is multiplied by the degree of involvement for each anatomic region and then multiplied by a constant and summed to yield the EASI score.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Apremilast</title>
            <description>Apremilast is being evaluated at daily doses of 20 mg PO twice daily (BID) for 12 weeks of treatment (treatment phase) in subjects with recalcitrant plaque-type AD or ACD.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Achieving 75% Reduction in Eczema Area and Severity Index (EASI) Score at Week 12 in Reference to Week 0</title>
          <description>EASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, edema, lichenification, and excoriations/erosions are scored on a scale of 0 (none) to 3 (severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 to 6. The total qualitative score is multiplied by the degree of involvement for each anatomic region and then multiplied by a constant and summed to yield the EASI score.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Achieving 50% Reduction in Eczema Area and Severity Index (EASI) Score at Week 12 in Reference to Week 0</title>
        <description>EASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, edema, lichenification, and excoriations/erosions are scored on a scale of 0 (none) to 3 (severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 to 6. The total qualitative score is multiplied by the degree of involvement for each anatomic region and then multiplied by a constant and summed to yield the EASI score.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Apremilast</title>
            <description>Apremilast is being evaluated at daily doses of 20 mg PO twice daily (BID) for 12 weeks of treatment (treatment phase) in subjects with recalcitrant plaque-type AD or ACD.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Achieving 50% Reduction in Eczema Area and Severity Index (EASI) Score at Week 12 in Reference to Week 0</title>
          <description>EASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, edema, lichenification, and excoriations/erosions are scored on a scale of 0 (none) to 3 (severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 to 6. The total qualitative score is multiplied by the degree of involvement for each anatomic region and then multiplied by a constant and summed to yield the EASI score.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>10 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Apremilast</title>
          <description>Apremilast is being evaluated at daily doses of 20 mg PO twice daily (BID) for 12 weeks of treatment (treatment phase) in subjects with recalcitrant plaque-type AD or ACD.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis 2nd to Atopic Dermatitis</sub_title>
                <description>This patient was in the screening phase of the trial and never received study medication. The subject was not eligible to enroll in trial due to the infection and flare of dermatitis.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>b12 deficiency</sub_title>
                <description>pcp screening</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>asymptomatic sinus arrythmia per EKG</sub_title>
                <description>routine EKG</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <description>routine questioning at visit</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>ectropion</sub_title>
                <description>routine questioning at visit</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>atopic blepharoconjunctivitis</sub_title>
                <description>routine questioning at visit</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>meibomian gland dysfunction</sub_title>
                <description>routine questioning at visits</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <description>routine questioning at visit</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>GI upset</sub_title>
                <description>routine questioning at visit</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>soft stool</sub_title>
                <description>routine questioning at visit</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>flatulence</sub_title>
                <description>routine questioning at visit</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>increase in number of stools</sub_title>
                <description>routine questioning at visits</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>diverticulosis</sub_title>
                <description>screening colonoscopy</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>internal hemorrhoids</sub_title>
                <description>screening colonoscopy</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>upper respiratory infection</sub_title>
                <description>routine questioning at visit</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>foot fracture after mechanical fall</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>lower back pain 2nd to motor vehicle accident (minor)</sub_title>
                <description>routine questioning at visits</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>routine questioning at visit</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>rigors</sub_title>
                <description>routine questioning at visit</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>insomnia</sub_title>
                <description>routine questioning at visit</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>myalgias</sub_title>
                <description>routine questioning at visits</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>chills</sub_title>
                <description>routine questioning at visits</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Burn</sub_title>
                <description>routine questioning at visit</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>dermatitis flare</sub_title>
                <description>routine questioning at visit</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>seborrheic dermatitis</sub_title>
                <description>routine questioning at visit</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>facial irritation from ketoconazole</sub_title>
                <description>routine questioning at visit</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>hair dye allergy</sub_title>
                <description>routine questioning at visits</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>scraped shin from mechanical injury</sub_title>
                <description>routine questioning at visits</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>nodules in breasts</sub_title>
                <description>physical examination (routine)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>MSSA skin infection</sub_title>
                <description>routine questioning at visits</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This was a small, single-arm open-label study with no placebo or comparison group to serve as a control.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Alice B Gottlieb, MD, PhD</name_or_title>
      <organization>Tufts Medical Center</organization>
      <phone>617 636 4802</phone>
      <email>agottlieb@tuftsmedicalcenter.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

